Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001072613-25-000167
Filing Date
2025-02-14
Accepted
2025-02-14 16:55:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16975
2 AGREEMENT exh1_18926.htm EX-1 16729
  Complete submission text file 0001072613-25-000167.txt   35389
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund IX, L.P. (Filed by) CIK: 0001666306 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Subject) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91369 | Film No.: 25630379
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)